Document:

<PAGE>

                                 NEONYOYO, INC
                                2000 STOCK PLAN
                            STOCK OPTION AGREEMENT

     Unless otherwise defined herein, the terms defined in the Plan shall have
the same defined meanings in this Option Agreement.

I.   NOTICE OF STOCK OPTION GRANT
     ----------------------------

     The undersigned Optionee has been granted an Option to purchase Common
Stock of the Company, subject to the terms and conditions of the Plan and this
Option Agreement, as follows:

     Date of Grant:

     Vesting Commencement Date:

     Exercise Price per Share:          $

     Total Number of Shares Granted:

     Total Exercise Price:

     Type of Option:                    ____  Incentive Stock Option

                                        ___  Nonstatutory Stock Option

     Term/Expiration Date:

     Vesting Schedule:
     ----------------

     This Option shall be exercisable, in whole or in part, according to the
following vesting schedule:

     25% of the Shares subject to the Option shall vest twelve months after the
Vesting Commencement Date, and 1/48 of the Shares subject to the Option shall
vest each month thereafter, subject to Optionee's continuing to be a Service
Provider on such dates.

     Termination Period:
     ------------------

     This Option shall be exercisable for three months after Optionee ceases to
be a Service Provider.  Upon Optionee's death or Disability, this Option may be
exercised for one year after Optionee ceases to be a Service Provider.  In no
event may Optionee exercise this Option after the Term/Expiration Date as
provided above.

II.  AGREEMENT
     ---------

     1.   Grant of Option.  The Plan Administrator of the Company hereby grants
          ---------------
to the Optionee named in the Notice of Grant (the "Optionee"), an option (the
"Option") to purchase the number of Shares set forth in the Notice of Grant, at
the exercise price per Share set forth in the Notice of Grant (the "Exercise
Price"), and subject to the terms and conditions of the Plan, which is
incorporated herein by reference.  Subject to Section 14(c) of the Plan, in the
event of a conflict between the terms and conditions of the Plan and this Option
Agreement, the terms and conditions of the Plan shall prevail.
<PAGE>

          If designated in the Notice of Grant as an Incentive Stock Option
("ISO"), this Option is intended to qualify as an Incentive Stock Option as
defined in Section 422 of the Code.  Nevertheless, to the extent that it exceeds
the $100,000 rule of Code Section 422(d), this Option shall be treated as a
Nonstatutory Stock Option ("NSO").

     2.   Exercise of Option.
          ------------------

          (a) Right to Exercise.  This Option shall be exercisable during its
              -----------------
term in accordance with the Vesting Schedule set out in the Notice of Grant and
with the applicable provisions of the Plan and this Option Agreement.

          (b) Method of Exercise.  This Option shall be exercisable by delivery
              ------------------
of an exercise notice in the form attached as Exhibit A (the "Exercise Notice")
which shall state the election to exercise the Option, the number of Shares with
respect to which the Option is being exercised, and such other representations
and agreements as may be required by the Company.  The Exercise Notice shall be
accompanied by payment of the aggregate Exercise Price as to all Exercised
Shares.  This Option shall be deemed to be exercised upon receipt by the Company
of such fully executed Exercise Notice accompanied by the aggregate Exercise
Price.

          No Shares shall be issued pursuant to the exercise of an Option unless
such issuance and such exercise complies with Applicable laws.  Assuming such
compliance, for income tax purposes the Shares shall be considered transferred
to the Optionee on the date on which the Option is exercised with respect to
such Shares.

     3.   Optionee's Representations.  In the event the Shares have not been
          --------------------------
registered under the Securities Act of 1933, as amended, at the time this Option
is exercised, the Optionee shall, if required by the Company, concurrently with
the exercise of all or any portion of this Option, deliver to the Company his or
her Investment Representation Statement in the form attached hereto as Exhibit B
[and shall read the applicable rules of the Commissioner of Corporations
attached to such Investment Representation Statement].

     4.   Lock-Up Period.  Optionee hereby agrees that, if so requested by the
          --------------
Company or any representative of the underwriters (the "Managing Underwriter")
in connection with any registration of the offering of any securities of the
Company under the Securities Act, Optionee shall not sell or otherwise transfer
any Shares or other securities of the Company during the 180-day period (or such
other period as may be requested in writing by the Managing Underwriter and
agreed to in writing by the Company) (the "Market Standoff Period") following
the effective date of a registration statement of the Company filed under the
Securities Act.  Such restriction shall apply only to the first registration
statement of the Company to become effective under the Securities Act that
includes securities to be sold on behalf of the Company to the public in an
underwritten public offering under the Securities Act.  The Company may impose
stop-transfer instructions with respect to securities subject to the foregoing
restrictions until the end of such Market Standoff Period.

     5.   Method of Payment.  Payment of the aggregate Exercise Price shall be
          -----------------
by any of the following, or a combination thereof, at the election of the
Optionee:

          (a)  cash or check;

          (b) consideration received by the Company under a formal cashless
exercise program adopted by the Company in connection with the Plan; or
<PAGE>

          (c) surrender of other Shares which, (i) in the case of Shares
acquired upon exercise of an option, have been owned by the Optionee for more
than six (6) months on the date of surrender, and (ii) have a Fair Market Value
on the date of surrender equal to the aggregate Exercise Price of the Exercised
Shares.

     6.   Restrictions on Exercise.  This Option may not be exercised until such
          ------------------------
time as the Plan has been approved by the shareholders of the Company, or if the
issuance of such Shares upon such exercise or the method of payment of
consideration for such shares would constitute a violation of any Applicable
Law.

     7.   Non-Transferability of Option.  This Option may not be transferred in
          -----------------------------
any manner otherwise than by will or by the laws of descent or distribution and
may be exercised during the lifetime of Optionee only by Optionee.  The terms of
the Plan and this Option Agreement shall be binding upon the executors,
administrators, heirs, successors and assigns of the Optionee.

     8.   Term of Option.  This Option may be exercised only within the term set
          --------------
out in the Notice of Grant, and may be exercised during such term only in
accordance with the Plan and the terms of this Option.

     9.   Tax Consequences.  Set forth below is a brief summary as of the date
          ----------------
of this Option of some of the federal tax consequences of exercise of this
Option and disposition of the Shares.  THIS SUMMARY IS NECESSARILY INCOMPLETE,
AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE.  THE OPTIONEE SHOULD
CONSULT A TAX ADVISER BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES.

          (a) Exercise of ISO.  If this Option qualifies as an ISO, there will
              ---------------
be no regular federal income tax liability upon the exercise of the Option,
although the excess, if any, of the Fair Market Value of the Shares on the date
of exercise over the Exercise Price will be treated as an adjustment to the
alternative minimum tax for federal tax purposes and may subject the Optionee to
the alternative minimum tax in the year of exercise.

          (b) Exercise of Nonstatutory Stock Option.  There may be a regular
              -------------------------------------
federal income tax liability upon the exercise of a Nonstatutory Stock Option.
The Optionee will be treated as having received compensation income (taxable at
ordinary income tax rates) equal to the excess, if any, of the Fair Market Value
of the Shares on the date of exercise over the Exercise Price.  If Optionee is
an Employee or a former Employee, the Company will be required to withhold from
Optionee's compensation or collect from Optionee and pay to the applicable
taxing authorities an amount in cash equal to a percentage of this compensation
income at the time of exercise, and may refuse to honor the exercise and refuse
to deliver Shares if such withholding amounts are not delivered at the time of
exercise.

          (c) Disposition of Shares.  In the case of an NSO, if Shares are held
              ---------------------
for at least one year, any gain realized on disposition of the Shares will be
treated as long-term capital gain for federal income tax purposes.  In the case
of an ISO, if Shares transferred pursuant to the Option are held for at least
one year after exercise and of at least two years after the Date of Grant, any
gain realized on disposition of the Shares will also be treated as long-term
capital gain for federal income tax purposes.  If Shares purchased under an ISO
are disposed of within one year after exercise or two years after the Date of
Grant, any gain realized on such disposition will be treated as compensation
income (taxable at ordinary income rates) to the extent of the difference
between the Exercise Price and the lesser of (1) the Fair Market Value of the
Shares
<PAGE>

on the date of exercise, or (2) the sale price of the Shares. Any additional
gain will be taxed as capital gain, short-term or long-term depending on the
period that the ISO Shares were held.

          (d) Notice of Disqualifying Disposition of ISO Shares.  If the Option
              -------------------------------------------------
granted to Optionee herein is an ISO, and if Optionee sells or otherwise
disposes of any of the Shares acquired pursuant to the ISO on or before the
later of (1) the date two years after the Date of Grant, or (2) the date one
year after the date of exercise, the Optionee shall immediately notify the
Company in writing of such disposition.  Optionee agrees that Optionee may be
subject to income tax withholding by the Company on the compensation income
recognized by the Optionee.

     10.  Entire Agreement; Governing Law.  The Plan is incorporated herein by
          -------------------------------
reference.  The Plan and this Option Agreement constitute the entire agreement
of the parties with respect to the subject matter hereof and supersede in their
entirety all prior undertakings and agreements of the Company and Optionee with
respect to the subject matter hereof, and may not be modified adversely to the
Optionee's interest except by means of a writing signed by the Company and
Optionee.  This agreement is governed by the internal substantive laws but not
the choice of law rules of California.

     11.  No Guarantee of Continued Service.  OPTIONEE ACKNOWLEDGES AND AGREES
          ---------------------------------
THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED
ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (NOT THROUGH
THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES
HEREUNDER).  OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE
TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO
NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A
SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL
NOT INTERFERE IN ANY WAY WITH OPTIONEE'S RIGHT OR THE COMPANY'S RIGHT TO
TERMINATE OPTIONEE'S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR
WITHOUT CAUSE.

     Optionee acknowledges receipt of a copy of the Plan and represents that he
or she is familiar with the terms and provisions thereof, and hereby accepts
this Option subject to all of the terms and provisions thereof.  Optionee has
reviewed the Plan and this Option in their entirety, has had an opportunity to
obtain the advice of counsel prior to executing this Option and fully
understands all provisions of the Option.  Optionee hereby agrees to accept as
binding, conclusive and final all decisions or interpretations of the
Administrator upon any questions arising under the Plan or this Option.
Optionee further agrees to notify the Company upon any change in the residence
address indicated below.

OPTIONEE:                                    NEONYOYO, INC.

                                             ____________________________
Signature                                    By

                                             ____________________________
Name                                         Title

Residence Address:
-----------------
<PAGE>

                                   EXHIBIT A
                                2000 STOCK PLAN
                                EXERCISE NOTICE

Neonyoyo, Inc.
328 Camino Sobrante
Orinda, CA  94563

Attn:  Secretary

     1.   Exercise of Option.  Effective as of today, __________,_______, the
undersigned ("Optionee") hereby elects to exercise Optionee's option to purchase
shares of the Common Stock (the "Shares") of Neonyoyo, Inc. (the "Company")
under and pursuant to the 2000 Stock Plan (the "Plan") and the [_] Incentive [_]
Nonstatutory Stock Option Agreement dated ____________,________, (the "Option
Agreement").

     2.   Delivery of Payment.  Purchaser herewith delivers to the Company the
full purchase price of the Shares, as set forth in the Option Agreement.

     3.   Representations of Optionee.  Optionee acknowledges that Optionee has
received, read and understood the Plan and the Option Agreement and agrees to
abide by and be bound by their terms and conditions.

     4.   Rights as Shareholder.  Until the stock certificate evidencing such
Shares is issued (as evidenced by the appropriate entry on the books of the
Company or of a duly authorized transfer agent of the Company), no right to vote
or receive dividends or any other rights as a shareholder shall exist with
respect to the Optioned Stock, notwithstanding the exercise of the Option.  The
Company shall issue (or cause to be issued) such stock certificate as soon as
practicable after the Option is exercised.  No adjustment will be made for a
dividend or other right for which the record date is prior to the date the stock
certificate is issued, except as provided in Section 12 of the Plan.

     5.   Right of First Refusal.  Before any Shares may be sold or transferred
(including transfer by operation of law), such Shares shall first be offered to
the Company (the "Right of First Refusal").

          (a) Notice of Proposed Transfer.  The Holder of the Shares shall
deliver a written notice ("Notice") stating (i) his bona fide intention to sell
or transfer such Shares, (ii) the number of such Shares to be sold or
transferred, (iii) the bona fide price or other consideration for which he
proposes to sell or transfer such Shares (the "Offered Price"), and the Holder
shall offer the Shares at the Offered Price to the Company or its assignee(s).

          (b) Exercise of Right of First Refusal.  At anytime within thirty (30)
              ----------------------------------
days after receipt of the Notice, the Company and/or its assignee(s) may, by
giving written notice to the Holder, elect to purchase all, but not less than
all, of the Shares proposed to be transferred to any one or more of the Proposed
Transferees, at the purchase price determined in accordance with subsection (c)
below.

          (c) Purchase Price.  The purchase price ("Purchase Price") for the
              --------------
Shares purchased by the Company or its assignee(s) under this Section shall be
the Offered Price.  If the Offered Price includes consideration other than cash,
the cash equivalent value of the non-cash consideration shall be determined by
the Board of Directors of the Company in good faith.
<PAGE>

          (d) Payment.  Payment of the Purchase Price shall be made, at the
              -------
option of the Company or its assignee(s), in cash (by check), by cancellation of
all or a portion of any outstanding indebtedness of the Holder to the Company
(or, in the case of repurchase by an assignee, to the assignee), or by any
combination thereof within 30 days after receipt of the Notice or in the manner
and at the times set forth in the Notice.

          (e) Holder's Right to Transfer.  If all of the Shares proposed in the
              --------------------------
Notice to be transferred to a given Proposed Transferee are not purchased by the
Company and/or its assignee(s) as provided in this Section, then the Holder may
sell or otherwise transfer such Shares to that Proposed Transferee at the
Offered Price or at a higher price, provided that such sale or other transfer is
consummated within 120 days after the date of the Notice, that any such sale or
other transfer is effected in accordance with any applicable securities laws and
that the Proposed Transferee agrees in writing that the provisions of this
Section shall continue to apply to the Shares in the hands of such Proposed
Transferee.  If the Shares described in the Notice are not transferred to the
Proposed Transferee within such period, a new Notice shall be given to the
Company, and the Company and/or its assignees shall again be offered the Right
of First Refusal before any Shares held by the Holder may be sold or otherwise
transferred.

          (f) Exception for Certain Family Transfers.  Anything to the contrary
              --------------------------------------
contained in this Section notwithstanding, the transfer of any or all of the
Shares during the Optionee's lifetime or on the Optionee's death by will or
intestacy to the Optionee's immediate family or a trust for the benefit of the
Optionee's immediate family shall be exempt from the provisions of this Section.
"Immediate Family" as used herein shall mean spouse, lineal descendant or
antecedent, father, mother, brother or sister.  In such case, the transferee or
other recipient shall receive and hold the Shares so transferred subject to the
provisions of this Section, and there shall be no further transfer of such
Shares except in accordance with the terms of this Section.

          (g) Termination of Right of First Refusal.  The Right of First Refusal
              -------------------------------------
shall terminate as to any Shares upon the first sale of Common Stock of the
Company to the general public pursuant to a registration statement filed with
and declared effective by the Securities and Exchange Commission under the
Securities Act of 1933, as amended.

     6.   Tax Consultation.  Optionee understands that Optionee may suffer
          ----------------
adverse tax consequences as a result of Optionee's purchase or disposition of
the Shares.  Optionee represents that Optionee has consulted with any tax
consultants Optionee deems advisable in connection with the purchase or
disposition of the Shares and that Optionee is not relying on the Company for
any tax advice.

     7.   Restrictive Legends and Stop-Transfer Orders.
          --------------------------------------------

          (a) Legends.  Optionee understands and agrees that the Company shall
              -------
cause the legends set forth below or legends substantially equivalent thereto,
to be placed upon any certificate(s) evidencing ownership of the Shares together
with any other legends that may be required by the Company or by state or
federal securities laws:

          THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
          UNDER THE SECURITIES ACT OF 1933 (THE "ACT") AND MAY NOT BE
          OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR
          HYPOTHECATED UNLESS AND UNTIL REGISTERED
<PAGE>

          UNDER THE ACT OR, IN THE OPINION OF COMPANY COUNSEL
          SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER,
          SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE
          THEREWITH.

          THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO
          CERTAIN RESTRICTIONS ON TRANSFER AND A RIGHT OF FIRST
          REFUSAL HELD BY THE ISSUER OR ITS ASSIGNEES) AS SET FORTH IN
          THE EXERCISE NOTICE BETWEEN THE ISSUER AND THE ORIGINAL
          HOLDER OF THESE SHARES, A COPY OF WHICH MAY BE OBTAINED AT
          THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER
          RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING ON
          TRANSFEREES OF THESE SHARES.

          IT IS UNLAWFUL TO CONSUMMATE A SALE OR TRANSFER OF THIS
          SECURITY, OR ANY INTEREST THEREIN, OR TO RECEIVE ANY
          CONSIDERATION THEREFOR, WITHOUT THE PRIOR WRITTEN CONSENT OF
          THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA,
          EXCEPT AS PERMITTED IN THE COMMISSIONER'S RULES.

          Optionee understands that transfer of the Shares may be restricted by
Section 260.141.11 of the Rules of the California Corporations Commissioner, a
copy of which is attached to Exhibit B, the Investment Representation Statement.

          (b) Stop-Transfer Notices.  Optionee agrees that, in order to ensure
              ---------------------
compliance with the restrictions referred to herein, the Company may issue
appropriate "stop transfer" instructions to its transfer agent, if any, and
that, if the Company transfers its own securities, it may make appropriate
notations to the same effect in its own records.

          (c) Refusal to Transfer.  The Company shall not be required (i) to
              -------------------
transfer on its books any Shares that have been sold or otherwise transferred in
violation of any of the provisions of this Agreement or (ii) to treat as owner
of such Shares or to accord the right to vote or pay dividends to any purchaser
or other transferee to whom such Shares shall have been so transferred.

     8.   Successors and Assigns.  The Company may assign any of its rights
          ----------------------
under this Agreement to single or multiple assignees, and this Agreement shall
inure to the benefit of the successors and assigns of the Company.  Subject to
the restrictions on transfer herein set forth, this Agreement shall be binding
upon Optionee and his or her heirs, executors, administrators, successors and
assigns.

     9.   Interpretation.  Any dispute regarding the interpretation of this
          --------------
Agreement shall be submitted by Optionee or by the Company forthwith to the
Administrator which shall review such dispute at its next regular meeting.  The
resolution of such a dispute by the Administrator shall be final and binding on
all parties.

     10.  Governing Law; Severability.  This Agreement is governed by the
          ---------------------------
internal substantive laws but not the choice of law rules, of California.
<PAGE>

     11.  Entire Agreement.  The Plan and Option Agreement are incorporated
          ----------------
herein by reference.  This Agreement, the Plan, the Option Agreement and the
Investment Representation Statement constitute the entire agreement of the
parties with respect to the subject matter hereof and supersede in their
entirety all prior undertakings and agreements of the Company and Optionee with
respect to the subject matter hereof, and may not be modified adversely to the
Optionee's interest except by means of a writing signed by the Company and
Optionee.
<PAGE>

Submitted by:                       Accepted by:

OPTIONEE:                           NEONYOYO, INC.

                                    ________________________________
Signature                           By

                                    ________________________________
Name                                Its

Address:                            Address:
-------                             -------
                                    328 Camino Sobrante
                                    Orinda, CA  94563

                                    ________________________________
                                    Date Received
<PAGE>

                                   EXHIBIT B
                      INVESTMENT REPRESENTATION STATEMENT

OPTIONEE:

COMPANY:       NEONYOYO, INC.

SECURITY:      COMMON STOCK

AMOUNT:

DATE:

     In connection with the purchase of the above-listed Securities, the
undersigned Optionee represents to the Company the following:

          (a) Optionee is aware of the Company's business affairs and financial
condition and has acquired sufficient information about the Company to reach an
informed and knowledgeable decision to acquire the Securities.  Optionee is
acquiring these Securities for investment for Optionee's own account only and
not with a view to, or for resale in connection with, any "distribution" thereof
within the meaning of the Securities Act of 1933, as amended (the "Securities
Act").

          (b) Optionee acknowledges and understands that the Securities
constitute "restricted securities" under the Securities Act and have not been
registered under the Securities Act in reliance upon a specific exemption
therefrom, which exemption depends upon, among other things, the bona fide
nature of Optionee's investment intent as expressed herein.  In this connection,
Optionee understands that, in the view of the Securities and Exchange
Commission, the statutory basis for such exemption may be unavailable if
Optionee's representation was predicated solely upon a present intention to hold
these Securities for the minimum capital gains period specified under tax
statutes, for a deferred sale, for or until an increase or decrease in the
market price of the Securities, or for a period of one year or any other fixed
period in the future.  Optionee further understands that the Securities must be
held indefinitely unless they are subsequently registered under the Securities
Act or an exemption from such registration is available.  Optionee further
acknowledges and understands that the Company is under no obligation to register
the Securities.  Optionee understands that the certificate evidencing the
Securities will be imprinted with a legend which prohibits the transfer of the
Securities unless they are registered or such registration is not required in
the opinion of counsel satisfactory to the Company, a legend prohibiting their
transfer without the consent of the Commissioner of Corporations of the State of
California and any other legend required under applicable state securities laws.

          (c) Optionee is familiar with the provisions of Rule 701 and Rule 144,
each promulgated under the Securities Act, which, in substance, permit limited
public resale of "restricted securities" acquired, directly or indirectly from
the issuer thereof, in a non-public offering subject to the satisfaction of
certain conditions.  Rule 701 provides that if the issuer qualifies under Rule
701 at the time of the grant of the Option to the Optionee, the exercise will be
exempt from registration under the Securities Act.  In the event the Company
becomes subject to the reporting requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, ninety (90) days thereafter (or such longer
period as any market stand-off agreement may require) the Securities exempt
under Rule 701 may be resold, subject to the satisfaction of certain of the
<PAGE>

conditions specified by Rule 144, including: (1) the resale being made through a
broker in an unsolicited "broker's transaction" or in transactions directly with
a market maker (as said term is defined under the Securities Exchange Act of
1934); and, in the case of an affiliate, (2) the availability of certain public
information about the Company, (3) the amount of Securities being sold during
any three month period not exceeding the limitations specified in Rule 144(e),
and (4) the timely filing of a Form 144, if applicable.

     In the event that the Company does not qualify under Rule 701 at the time
of grant of the Option, then the Securities may be resold in certain limited
circumstances subject to the provisions of Rule 144, which requires the resale
to occur not less than one year after the later of the date the Securities were
sold by the Company or the date the Securities were sold by an affiliate of the
Company, within the meaning of Rule 144; and, in the case of acquisition of the
Securities by an affiliate, or by a non-affiliate who subsequently holds the
Securities less than two years, the satisfaction of the conditions set forth in
sections (1), (2), (3) and (4) of the paragraph immediately above.

          (d) Optionee further understands that in the event all of the
applicable requirements of Rule 701 or 144 are not satisfied, registration under
the Securities Act, compliance with Regulation A, or some other registration
exemption will be required; and that, notwithstanding the fact that Rules 144
and 701 are not exclusive, the Staff of the Securities and Exchange Commission
has expressed its opinion that persons proposing to sell private placement
securities other than in a registered offering and otherwise than pursuant to
Rules 144 or 701 will have a substantial burden of proof in establishing that an
exemption from registration is available for such offers or sales, and that such
persons and their respective brokers who participate in such transactions do so
at their own risk.  Optionee understands that no assurances can be given that
any such other registration exemption will be available in such event.

          (e) Optionee understands that the certificate evidencing the
Securities will be imprinted with a legend which prohibits the transfer of the
Securities without the consent of the Commissioner of Corporations of
California.  Optionee has read the applicable Commissioner's Rules with respect
to such restriction, a copy of which is attached.

                                   Signature of Optionee:

                                   Date:_____________________, 2000
<PAGE>

                                 ATTACHMENT 1
             STATE OF CALIFORNIA - CALIFORNIA ADMINISTRATIVE CODE
             ----------------------------------------------------
         Title 10. Investment-Chapter 3. Commissioner of Corporations

260.141.11:  Restriction on Transfer.  (a) The issuer of any security upon which
----------  ------------------------
a restriction on transfer has been imposed pursuant to Sections 260.102.6,
260.141.10 or 260.534 shall cause a copy of this section to be delivered to each
issuee or transferee of such security at the time the certificate evidencing the
security is delivered to the issuee or transferee.

     (b)  It is unlawful for the holder of any such security to consummate a
sale or transfer of such security, or any interest therein, without the prior
written consent of the Commissioner (until this condition is removed pursuant to
Section 260.141.12 of these rules), except:

          (1)  to the issuer;

          (2)  pursuant to the order or process of any court;

          (3)  to any person described in Subdivision (i) of Section 25102 of
the Code or Section 260.105.14 of these rules:

          (4)  to the transferor's ancestors, descendants or spouse, or any
custodian or trustee for the account of the transferor or the transferor's
ancestors, descendants, or spouse; or to a transferee by a trustee or custodian
for the account of the transferee or the transferee's ancestors, descendants or
spouse;

          (5)  to holders of securities of the same class of the same issuer;

          (6)  by way of gift or donation inter vivos or on death;

          (7)  by or through a broker-dealer licensed under the Code (either
acting as such or as a finder) to a resident of a foreign state, territory or
country who is neither domiciled in this state to the knowledge of the broker-
dealer, nor actually present in this state if the sale of such securities is not
in violation of any securities law of the foreign state, territory or country
concerned;

          (8)  to a broker-dealer licensed under the Code in a principal
transaction, or as an underwriter or member of an underwriting syndicate or
selling group;

          (9)  if the interest sold or transferred is a pledge or other lien
given by the purchaser to the seller upon a sale of the security for which the
Commissioner's written consent is obtained or under this rule not required.

          (10) by way of a sale qualified under Sections 25111, 25112, 25113 or
25121 of the Code, of the securities to be transferred, provided that no order
under Section 25140 or subdivision (a) of Section 25143 is in effect with
respect to such qualification:

          (11) by a corporation to a wholly owned subsidiary of such
corporation, or by a wholly owned subsidiary of a corporation to such
corporation;

          (12) by way of an exchange qualified under Section 25111, 25112 or 251
13 of the Code, provided that no order under Section 25140 or subdivision (a) of
Section 25143 is in effect with respect to such qualification;

          (13) between residents of foreign states, territories or countries who
are neither domiciled nor actually present in this state;

          (14) to the State Controller pursuant to the Unclaimed Property Law or
to the administrator of the unclaimed property law of another state; or

          (15) by the State Controller pursuant to the Unclaimed Property Law or
by the administrator of the unclaimed property law of another state if, in
either such case, such person (i) discloses to potential purchasers at the sale
that transfer of the securities is restricted under this rule, (ii) delivers to
each purchaser a copy of this rule, and (iii) advises the Commissioner of the
name of each purchaser:

          (16) by a trustee to a successor trustee when such transfer does not
involve a change in the beneficial ownership of the securities;

          (17) by way of an offer and sale of outstanding securities in an
issuer transaction that is subject to the qualification requirement of Section
25110 of the Code but exempt from that qualification requirement by subdivision
(f) of Section 25102: provided that any such transfer is on the condition that
any certificate evidencing the security issued to such transferee shall contain
the legend required by this section.

     (c)  The certificates representing all such securities subject to such a
restriction on transfer, whether upon initial issuance or upon any transfer
thereof, shall bear on their face a legend, prominently stamped or printed
thereon in capital letters of not less than 10-point size, reading as follows:

          "IT IS UNLAWFUL TO CONSUMMATE A SALE OR TRANSFER OF THIS SECURITY, OR
          ANY INTEREST THEREIN, OR TO RECEIVE ANY CONSIDERATION THEREFOR,
          WITHOUT THE PRIOR WRITTEN CONSENT OF THE COMMISSIONER OF CORPORATIONS
          OF THE STATE OF CALIFORNIA, EXCEPT AS PERMITTED IN THE COMMISSIONER'S
          RULES."NATIONAL MEDICAL DIRECTOR AGREEMENT

                            (Independent Contractor)

     This National Medical Director  Agreement  ("Agreement") is entered into as
of March ___,  2000  ("Effective  Date") by and among  LIGHTTOUCH  VEIN & LASER,
INC.,  a Nevada  corporation  ("LightTouch")  and  HARLEY  F.  FREIBERGER,  M.D.
("Medical Director").

                                    RECITALS

     A.  Medical  Director  operates a medical  practice and has entered into an
agreement to provide  services for the LightTouch  Center located in Charleston,
South  Carolina,  known as LightTouch  Vein & Laser of South  Carolina,  Inc., a
South Carolina corporation,  a wholly owned subsidiary of LightTouch (the "South
Carolina Center").

     B. LightTouch engages in the business of owning laser centers and providing
certain administrative and support services concerning the day-to-day affairs of
medical practices and has established  existing laser centers ("Centers") at the
sites listed on EXHIBIT A, including the South Carolina Center.

     C. LightTouch  desires to engage Medical  Director to serve as the national
medical  director on behalf of  LightTouch  and all of the Centers,  and Medical
Director desires to serve in such capacity.

     NOW,  THEREFORE,  in  consideration  of the mutual covenants and conditions
contained herein, the parties agrees as follows:

                     I. RESPONSIBILITIES OF MEDICAL DIRECTOR

     1.1 MEDICAL DIRECTOR.  Medical Director shall assume responsibility for the
quality control and  professionalism of LightTouch and the Centers on a national
basis and shall  appoint,  if necessary,  the local  medical  directors for each
individual  Center.  Medical Director and the individual local medical directors
shall assist  LightTouch in the proper  operation and management of the Centers.
Medical  Director duties as the national  medical  director of the Centers shall
include the responsibilities listed on EXHIBIT B.

     1.2 QUALITY  ASSURANCE.  Medical  Director  shall monitor  utilization  and
quality of  services  provided by the Centers  and  LightTouch,  shall  develop,
maintain and administer quality assurance programs and performance standards and
shall  offer  suggestions  and  requirements  to  remedy   deficiencies  in  the
efficiency or the quality of medical care provided.  However,  Medical  Director
shall not be liable or responsible  for the failure of any Center to perform its
obligation  or the  negligence  of any Center in the  performance  of any of its
obligations and responsibilities.

                       II. RESPONSIBILITIES OF LIGHTTOUCH
<PAGE>

     2.1 RESPONSIBILITIES WITH REGARD TO SELECTED PATIENT-RELATED MATTERS.

          (a) RECORDKEEPING.  LightTouch shall assist the Centers in maintaining
patient medical records in accordance with applicable laws.  Notwithstanding the
foregoing  sentence,  patient  medical  records  shall be and shall  remain  the
property  of  the  Centers,   and  the  content  thereof  shall  be  solely  the
responsibility of the Centers.

          (b)  QUALITY  ASSURANCE.  LightTouch  shall  assist  the  Centers,  in
accordance with criteria established by the Centers and Medical Director, in the
development  and  implementation  of  appropriate  quality  assurance  programs,
including  development  of  performance  and  utilization  standards,   sampling
techniques for case review, and preparation of appropriately documented studies.
Notwithstanding  the  foregoing,  LightTouch  shall not  perform any duties that
constitute the corporate practice of medicine.

     2.2 OTHER RESPONSIBILITES.

          (a) INSURANCE. Within a reasonable period of time but by no later than
the time that Medical  Director  becomes a director of LightTouch as provided in
Section 4.2 below,  LightTouch shall obtain and maintain during the term of this
Agreement  directors and officers  liability  insurance and all other  liability
insurance in  sufficient  amounts to protect  Medical  Director from any and all
liability  which  he may  incur  in the  performance  of his  duties  hereunder.
LightTouch hereby indemnifies,  defends and holds Medical Director harmless from
and against any and all liabilities,  losses,  claims, causes of action, damages
and costs  including  reasonable  attorneys' fees arising from or as a result of
the performance of his duties hereunder.

          (b)  ACCOUNTING.  LightTouch  shall be solely  responsible  for legal,
accounting and other  professional  services incurred by Medical Director in the
performance of his duties  hereunder.  LightTouch  shall be responsible  for and
shall  provide at its expense all  accounting  services in  connection  with the
consolidation  of LightTouch and the South Carolina Center,  including,  without
limitation, all Securities Exchange Commission filings and reports.

                           III. FINANCIAL ARRANGEMENTS

          3.1  COMPENSATION.  As  compensation  for the  performance  by Medical
Director of the substantial services required hereunder on behalf of LightTouch,
LightTouch  shall transfer to Medical Director 447,205 shares of common stock of
LightTouch  having a value of One  Million  Eight  Hundred  Thousand  and no/100
Dollars  ($1,800,000.00)  based upon the average  closing price of  LightTouch's
common shares for the five trading days immediately  prior to the date hereof as
traded on the OTC Bulletin Board under the symbol "LTVL",  said stock to be held
by an affiliate  for purposes of Federal  Securities  Law. In addition  thereto,
LightTouch  shall transfer to Medical Director 124,224 shares of common stock of
LightTouch   having  a  value  of  Five  Hundred  Thousand  and  no/100

Charleston:  182738 v.6                  2
<PAGE>

Dollars  ($500,000.00)  as a bonus for entering into this Agreement and agreeing
to perform the duties of  national  medical  director  for  LightTouch.  Medical
Director  understands  and  acknowledges  that in  addition to  restrictions  on
transfer of the foregoing shares of stock  (collectively,  the "Stock") required
under the Federal  Securities Act of 1933,  the Stock is further  restricted and
subject to  forfeiture  in the event  Medical  Director  fails to  substantially
perform the duties of national  medical  director of  LightTouch as set forth in
this Agreement for the Initial Term of this Agreement.  In the event of a breach
in the  performance  of this duties  during the Initial Term,  Medical  Director
shall forfeit and return the Stock to LightTouch. Medical Director's interest in
the Stock shall not be deemed vested until the expiration of the Initial Term.

     3.2 PAID  EXPENSES AND  BENEFITS.  LightTouch  shall pay at its expense all
costs and expenses  incurred by Medical  Director,  including travel and related
expenses and cost of attendance,  for medical conferences,  meetings,  seminars,
meetings with prospective practices for future acquisition,  and other requested
travel on behalf of LightTouch when LightTouch  requests the presence of Medical
Director at any such conference or meeting and Medical Director consents to such
attendance. When any such attendance is requested by LightTouch, LightTouch will
not charge any such expense as an expense against the South Carolina Center.

     LightTouch  further agrees that any travel required of Medical  Director in
the  performance  of any of  Medical  Director's  duties  shall be first  class.
Furthermore,  Medical Director shall be entitled to stay in any hotel in which a
conference or meeting is being held where the  attendance at such  conference or
meeting is required or requested by LightTouch or otherwise permitted hereunder.
Any  other  non-required  travel  and  expenses  shall be  subject  to the prior
approval of LightTouch, which approval will not be unreasonably withheld.

     In order to facilitate  Medical  Director's travel and related expenses for
any such meetings, conferences or work on behalf of LightTouch, LightTouch shall
promptly  provide to Medical  Director a corporate  charge or credit card on the
account of  LightTouch,  the  expense  of which will not be charged  back to the
South Carolina Center.

                       IV. REPRESENTATIONS AND WARRANTIES

     4.1 COVENANTS AND WARRANTIES OF LIGHTTOUCH.  LightTouch  hereby  represents
and warrants to Medical Director as follows:

          (a) LightTouch is and shall remain during the term of this Agreement a
corporation which is duly organized, validly existing and in good standing under
the laws of the State of Nevada,  possessing  full corporate power and authority
to own its properties and to conduct the business in which it engages.

          (b) LightTouch  has full corporate  power and authority to execute and
deliver  this  Agreement  and to  engage  in the  transactions  and  obligations
contemplated  by this  Agreement.  Upon  its  execution,  this  Agreement  shall
constitute  a  valid  and  binding

Charleston:  182738 v.6                  3
<PAGE>

obligation of LightTouch,  enforceable in accordance  with its terms,  except as
limited by applicable bankruptcy,  insolvency, moratorium, or other similar laws
affecting  generally the rights of creditors  and by  principles of equity.  The
party  executing this Agreement on behalf of LightTouch is duly authorized to do
so.

          (c)  The  consummation  of  the  transactions   contemplated  by  this
Agreement will not: result in any breach of the terms,  provisions or conditions
of or constitute a default under the  Certificate of  Incorporation,  By-Laws or
other enabling or governing  instruments of LightTouch or any agreement to which
LightTouch  is a party or by which it is  bound;  or, to the best  knowledge  of
LightTouch, constitute a violation of any applicable law or regulation.

          (d) AUTHORIZED SHARES. LightTouch has authorized 100,000,000 shares of
capital stock and 25,000,000  shares of preferred  stock.  Each of the shares of
Stock  has  been  duly  authorized  and  validly  issued,   is  fully  paid  and
non-assessable  and was issued by LightTouch in compliance  with all  applicable
federal  and State  securities  laws and all  applicable  rules and  regulations
thereunder.

          (e) APPROVAL OF TRANSFER. LightTouch acknowledges that it has approved
the transfer of the Stock by LightTouch to Medical  Director in accordance  with
the requirements of all securities laws and any buy-sell agreement pertaining to
the sale of shares of stock of LightTouch.

          (f) TITLE. LightTouch has good and marketable title to the Stock being
transferred  to Medical  Director  and has the absolute  right to sell,  assign,
transfer  and  deliver  such  Stock to  Medical  Director  free and clear of any
security  interest,   lien  or  encumbrance,   subject,   however,   to  certain
restrictions on transfer as set forth on the certificates.

     4.2 BOARD OF  DIRECTORS.  LightTouch  shall appoint  Medical  Director as a
director of the board of directors of LightTouch after the due date of the first
installment of principal  under the promissory  note from  LightTouch to Medical
Director dated on or about the date hereof.

                             V. TERM AND TERMINATION

     5.1 TERM.  This  Agreement  shall  commence on the Effective Date and shall
continue  for a period of twelve  (12)  months  ending on April 1, 2001,  unless
sooner terminated  pursuant to this Article V (the "Initial Term").  Thereafter,
this Agreement shall  automatically  continue in effect for additional  terms of
five (5) years each,  unless either party notifies the other in writing not less
than six (6) months or more than twelve (12) months prior to the  expiration  of
the term or any renewal  term of its intent to terminate  this  Agreement at the
end of such term,  or unless this  Agreement is  terminated  pursuant to Section
5.2, Section 5.3 or Section 8.10 hereof.  Notwithstanding  the

Charleston:  182738 v.6                  4
<PAGE>

foregoing,  if at any time after the Initial Term,  Medical Director  determines
that his  responsibilities  hereunder are interfering  with the operation of his
practice  and the  performance  of his duties at the South  Carolina  Center and
LightTouch  fails to provide  assistance  satisfactory  to Medical  Director  at
LightTouch's  expense  within  thirty (30) days of Medical  Director's  request,
Medical Director may terminate this Agreement upon the expiration of such thirty
(30) day period. If Medical Director fails to perform his obligations  hereunder
and is in breach of this Agreement  prior to the expiration of the Initial Term,
Medical  Director  shall forfeit and return all Stock  received as  compensation
pursuant to Section 3.1 of this Agreement.

     5.2 EVENTS OF DEFAULT.  Each of the following shall constitute an "Event of
Default" (the party causing such default is referred to as the "Breaching Party"
and the other party is referred to as the "Non-Breaching Party"):

          (a) The Breaching Party fails to make any payment  required under this
Agreement, which is not cured within ten (10) days of written notice therefor.

          (b) The  Breaching  Party fails to observe or  otherwise  breaches any
material term, condition,  covenant, or warranty of this Agreement, which is not
cured within sixty (60) days of written notice.

     5.3  TERMINATION.  Subject  to  the  provisions  of  this  Article  V,  The
Non-Breaching Party may terminate this Agreement upon the occurrence of an Event
of Default in accordance with the following:

          (a) In the event of the occurrence of an Event of Default  referred to
in Section  5.2(a)  above,  upon the  expiration  of ten (10) days after written
notice,  which notice  shall  specify the amount of such payment and when it was
due, unless the amount due is paid within such ten (10) days.

          (b) In the event of the occurrence of any other Event of Default, upon
the  expiration  of sixty (60) days after  written  notice,  which  notice shall
specify the nature and extent of such Event of Default to the  Breaching  Party,
unless such Event of Default is remedied  within such sixty (60) days or, in the
case of an Event of Default  which cannot  reasonably  be remedied  within sixty
(60) days,  unless the Breaching  Party has made a good faith effort to begin to
cure such Event of Default within such sixty (60) days.

         5.4      DUTIES UPON TERMINATION OR EXPIRATION OF THIS AGREEMENT.

          (a) If this  Agreement is terminated  upon  expiration of its term, or
earlier as provided in Sections 5.3 or 8.10:

               (i)  Neither  party  shall be  released  or  discharged  from any
obligation,  debt or liability which has previously accrued or been incurred and
remains to be performed upon the date of termination or expiration;

Charleston:  182738 v.6                  5
<PAGE>

               (ii) Any sums of money  owing by one party to the other  shall be
paid immediately;

               (iii) Medical  Director  shall return to LightTouch all originals
and copies of the  Proprietary  Information of any of the Protected  Parties (as
those terms are defined in Article  VI) which are in the  possession  of Medical
Director or any other person or entity to whom it has delivered  such  originals
and copies; and

               (iv) Damages and any other remedies available at law or in equity
may be sought and collected by the Non-Breaching  Party from the Breaching Party
in the event of a termination pursuant to Section 5.3 hereof.

          (b) If this  Agreement is  terminated  prior to the  expiration of the
Initial Term, Medical Director shall forfeit and return the Stock as required in
Sections 3.1 and 5.1 of this Agreement.

                            VI. RESTRICTIVE COVENANTS

     6.1  COVENANT  REGARDING  PROPRIETARY  INFORMATION.  In the  course  of the
relationship  created  pursuant to this  Agreement,  Medical  Director will have
access to certain methods, trade secrets, processes, ideas, systems, procedures,
inventions,  discoveries,  concepts,  software in various stages of development,
designs,  drawings,  specifications,  models, data,  documents,  diagrams,  flow
charts,  research,  economic and financial analysis,  developments,  procedures,
know-how,  policy manuals,  financial  data, form contracts,  marketing ad other
techniques,   plans,  materials,   forms,   copyrightable  materials  and  trade
information  regarding the  operations of  LightTouch  and/or of its  Affiliates
(collectively,  the  "Protected  Parties").  The  foregoing,  together  with the
existence  and terms of this  Agreement,  are  referred to in this  Agreement as
"Proprietary Information".  Medical Director shall maintain all such Proprietary
Information  in strict  secrecy and shall not divulge  such  information  to any
third parties, except to its accountants, financial and legal advisors as may be
necessary for the discharge of its obligations under this Agreement. The parties
recognize that a breach of this Section 6.1 cannot be adequately  compensated in
money damages and therefore agree that  injunctive  relief shall be available to
the Protected Parties as their respective interests may appear.

     The obligations of Medical  Director under this Section 6.1 shall not apply
to information: (i) which is a matter of public knowledge on or becomes a matter
of public knowledge after the Effective Date of this Agreement,  other than as a
breach  of the  confidentiality  terms of this  Agreement  or as a breach of the
confidentiality  terms of any  other  agreement  between  Medical  Director  and
LightTouch or its Affiliates;  or (ii) was lawfully obtained by Medical Director
on a  nonconfidential  basis other than in the course of performance  under this
Agreement and from some entity other than  LightTouch or its  Affiliates or from
some person other than one employed or engaged by LightTouch or its  Affiliates,
which entity or person has no obligation of confidentiality to LightTouch or its
Affiliates.

Charleston:  182738 v.6                  6
<PAGE>

                          VII. INFORMATION AND RECORDS

7.1  OWNERSHIP  OF  RECORDS.  At all  times  during  and  after the term of this
Agreement,  including any extensions or renewals hereof,  all business  records,
including but not limited to,  business  agreements,  books of account,  general
administrative  records and all information  generated under or contained in the
management information system pertaining to LightTouch's  obligations hereunder,
and other business information of any kind or nature, except for patient medical
records and  Medical  Director's  and the South  Carolina  Center's  Records (as
defined  in  Section  7.2  below),  shall be and  remain  the sole  property  of
LightTouch;  PROVIDED that after  termination of this Agreement Medical Director
and the South  Carolina  Center shall be entitled to  reasonable  access to such
records and information,  including the right to obtain copies thereof,  for any
purpose  related to patient care or the defense of any claim relating to patient
care or the business of  LightTouch or Medical  Director and the South  Carolina
Center.

     7.2 MEDICAL DIRECTOR'S  BUSINESS AND FINANCIAL RECORDS. At all times during
and after the term of this  Agreement,  the  financial,  corporate and personnel
records and information  relating  exclusively to the business and activities of
Medical  Director  and the South  Carolina  Center,  as  distinguished  from the
business  and  activity  of  LightTouch,  hereinafter  referred  to as  "Medical
Director's and the South  Carolina  Center's  Records,"  shall be and remain the
sole property of Medical Director and the South Carolina Center.

     7.3 ACCESS TO RECORDS. Each party shall be entitled,  upon request and with
reasonable  advance  notice,  to obtain access to all records of the other party
directly related to the performance of such party's obligations pursuant to this
Agreement;  provided,  however,  that such  right  shall not allow for access to
records  that  must  necessarily  be kept  confidential.  Either  party,  at its
expense,  shall  have the right to make  copies of any  records  to which it has
access pursuant to this Section.

     7.4 CONFIDENTIALITY OF RECORDS. LightTouch and Medical Director shall adopt
procedures for maintaining the  confidentiality  of the records  relating to the
operations  of  LightTouch   and  Medical   Director  which  do  not  constitute
Proprietary  Information,  which information is not otherwise available to third
parties  publicly or by law,  and shall comply with all  applicable  federal and
state statutes and regulations relating to such records. Patient medical records
and other privileged  patient  information shall not be disclosed or utilized by
LightTouch  or their  agents or  employees  except as required or  permitted  by
applicable laws and regulations.

                               VIII. MISCELLANEOUS

     8.1  INDEPENDENT  CONTRACTOR  STATUS OF PARTIES.  IN THE PERFORMANCE OF THE
WORK, DUTIES AND OBLIGATIONS UNDER THIS AGREEMENT, IT IS MUTUALLY UNDERSTOOD AND
AGREED THAT EACH PARTY IS AT ALL TIMES ACTING AND  PERFORMING AS AN  INDEPENDENT
CONTRACTOR  WITH RESPECT TO THE OTHER AND THAT NO  RELATIONSHIP

Charleston:  182738 v.6                  7
<PAGE>

OF PARTNERSHIP JOINT VENTURE OR EMPLOYMENT IS CREATED BY THIS AGREEMENT. NEITHER
PARTY, NOR ANY OTHER PERSON PERFORMING SERVICES ON BEHALF OF SUCH PARTY PURSUANT
TO THIS  AGREEMENT,  SHALL HAVE ANY RIGHT OR CLAIM  AGAINST  THE OTHER PARTY FOR
SOCIAL SECURITY BENEFITS, WORKERS' COMPENSATIONS BENEFITS,  DISABILITY BENEFITS,
UNEMPLOYMENT  INSURANCE BENEFITS,  HEALTH BENEFITS,  VACATION PAY, SICK LEAVE OR
ANY OTHER EMPLOYEE BENEFITS OF ANY KIND.

     8.2 NO WAIVER.  The waiver by any party to this  Agreement of any breach of
any term or  condition  of this  Agreement  shall  not  constitute  a waiver  of
subsequent  breaches.  No waiver by any party of any provision of this Agreement
shall be deemed to constitute a waiver of any other provision.

     8.3  NOTICES.  If, at any time after the  execution of this  Agreement,  it
shall become necessary or convenient for one of the parties to serve any notice,
demand  or  communication  upon  the  other  party,  such  notice,   demand,  or
communication shall be in writing and shall be served personally,  by nationally
recognized  overnight  courier which provides  confirmation  of delivery,  or by
depositing the same in the United States mail,  registered or certified,  return
receipt requested, postage prepaid and,

          (a) If  intended  for  Medical  Director,  then  the  notice  shall be
addressed to:

                           29 Gamecock Avenue
                           Charleston, South Carolina  29407
                           Attn:  Harley F. Freiberger, M.D.

          (b) If intended for LightTouch, then the notice shall be addressed to:

                           LightTouch Vein & Laser, Inc.
                           10663 Montgomery Road
                           Cincinnati, Ohio  45242
                           Attn:  Greg Martini

or to such other  address as either party may have  furnished to the other party
in writing as the place for the service of notice. Any notice so mailed shall be
deemed to have been given  three (3) days after the same has been  deposited  in
the United States mail; when delivered if the same has been given personally; or
the next business day if the same has been delivered to a nationally  recognized
overnight courier service.

         8.4 ASSIGNMENT.  Neither party may sell, transfer, assign, or otherwise
convey its rights or obligations  under this Agreement without the prior written
consent  of  the  other,  which  consent  shall  not be  unreasonably  withheld;
provided,  however,  Medical  Director may assign this  Agreement and all of his
rights  and  obligations  hereunder  to a

Charleston:  182738 v.6                  8
<PAGE>

professional  corporation  or similar  business  entity  wholly owned by Medical
Director without the prior consent of LightTouch.

     8.5  SUCCESSORS  AND ASSIGNS.  Subject to the  provisions of this Agreement
respecting  assignment,  the terms,  covenants and conditions  contained  herein
shall be binding upon and inure to the benefit of the  successors  and permitted
assigns of the parties hereto.

     8.6 SEVERABILITY. Nothing contained in this Agreement shall be construed to
require the  commission  of an act contrary to law,  and  whenever  there is any
conflict between any provision of this Agreement and any statute, law, ordinance
or regulation, the latter shall prevail. In such event, and in any case in which
any  provision of this  Agreement is determined to be in violation of a statute,
law, ordinance or regulation, the affected provision(s) shall be limited only to
the extent necessary to bring it within the requirements of the law and, insofar
as  possible  under  the  circumstances,  to  carry  out  the  purposes  of this
Agreement. The other provisions of this Agreement shall remain in full force and
effect, and the invalidity or unenforceability of any provision hereof shall not
affect  the  validity  and  enforceability  of  the  other  provisions  of  this
Agreement,  nor the availability of all remedies in law or equity to the parties
with respect to such other provisions.

     8.7 HEADINGS.  The headings used in the  Agreement are for  convenience  of
reference  only and  shall  have no  force  or  effect  in the  construction  or
interpretation of the provisions of this Agreement.

     8.8 TIME OF THE ESSENCE. Time is of the very essence of each and all of the
agreements, covenants and conditions of this Agreement.

     8.9 GOVERNING LAW. This Agreement  shall be interpreted in accordance  with
and governed by the laws of the State of South Carolina,  to the jurisdiction of
which each of the parties hereby submits.

     8.10 CONTRACT  MODIFICATIONS FOR PROSPECTIVE LEGAL EVENTS. In the event any
state or federal laws or  regulations,  now  existing or enacted or  promulgated
after  the  Effective  Date of  this  Agreement,  are  interpreted  by  judicial
decision,  a regulatory agency or legal counsel of both parties in such a manner
as to indicate that the structure of this  Agreement may be in violation of such
laws or  regulations  (a  "Structural  Issue"),  either party may terminate this
Agreement,  on not less than ninety (90) days written notice to the other party,
or negotiate and enter into an amendment of the  provisions of this Agreement in
such manner as to alleviate  such  violation.  In the event that the parties are
unable  to  agree  upon  such  amendment  within  thirty  (30)  days  after  the
determination  that such  amendment  is  necessary,  a party may elect either to
terminate  this  Agreement,  on not less than ninety (90) days written notice to
the other party.

     8.11  LANGUAGE  CONSTRUCTION.  The language in all parts of this  Agreement
shall be construed,  in all cases, according to its fair meaning, and not for or
against  either party

Charleston:  182738 v.6                  9
<PAGE>

hereto.  The parties  acknowledge  that each party and its counsel have reviewed
and  revised  this  Agreement  and that the normal rule of  construction  to the
effect that any ambiguities are to be resolved  against the drafting party shall
not be employed in the interpretation of this Agreement.

     8.12 INDEMNIFICATION.  LightTouch shall indemnify, hold harmless and defend
Medical  Director  from and against any and all  liabilities,  losses,  damages,
claims, causes of action, and expenses (including reasonable attorneys' fees and
disbursements  (a  "Medical  Director  Loss"),  caused or  asserted to have been
caused, directly or indirectly,  by or as a result of the performance of medical
services or any other acts or  omissions  by  LightTouch,  and/or its  partners,
agents,  employees and/or  subcontractors (other than Medical Director) and as a
result of the performance of Medical  Director's  obligations  hereunder  except
with  respect  to any  Medical  Director  Loss  which is the result of any gross
negligence or willful  misconduct by Medical  Director.  Medical  Director shall
indemnify,  hold  harmless  and  defend  LightTouch,  its  officers,  directors,
shareholders,  employees,  agents and independent  contractors  (the "LightTouch
Group")  from and  against any and all  liabilities,  losses,  damages,  claims,
causes  of  action,  and  expenses  (including  reasonable  attorneys'  fees and
disbursements  (a  "LightTouch  Loss"),  caused or asserted to have been caused,
directly or indirectly, by or as a result of the performance of medical services
or any other acts or omissions by Physician Group, and/or its partners,  agents,
employees and/or  subcontractors  (other than LightTouch) during the term hereof
except  with  respect  to any  LightTouch  Loss which is the result of any gross
negligence or willful misconduct by a member of the LightTouch Group.

     8.13 ENTIRE  AGREEMENT.  This Agreement  constitutes  the entire  agreement
between the parties with respect to the subject matter hereof and supersedes all
prior  and   contemporaneous   agreements,   understandings,   negotiations  and
discussions,  whether  written or oral,  between or among parties  regarding the
subject matter of this Agreement.

     8.14 INCORPORATION BY REFERENCE. All exhibits and other attachments to this
Agreement are incorporated by reference into this Agreement by such reference.

     8.15  AMENDMENTS  ONLY IN  WRITING.  This  Agreement  may not be amended or
modified in any respect whatsoever, except by an instrument in writing signed by
the parties hereto.

     8.16   COUNTERPARTS.   This  Agreement  may  be  executed  in  on  or  more
counterparts,  each of which shall be  considered  an original  and all of which
shall  constitute one and the same  agreement.  This Agreement  shall not become
effective until it has been executed by all of the parties hereto.

     8.17  COMMERCIAL  IMPRACTICABILITY.  No  party to this  Agreement  shall be
liable for any failure to perform its  obligations  hereunder where such failure
results from any cause beyond that party's reasonable  control,  including,  for
example,  an act of God,  labor  disturbance  such as a strike or walkout,  war,
riot,  fire,  storm,  accident,   government  regulation  or  interference,   or
mechanical, electronic or communications failure.

Charleston:  182738 v.6                  10
<PAGE>

     8.18  ELECTION OF  REMEDIES  The  respective  rights of the parties to this
Agreement  shall be  cumulative.  Each  party  shall  have all other  rights and
remedies  consistent  with this  Agreement  as law and  equity may  provide.  No
exercise by any party of one right or remedy  shall be deemed to be an exclusive
election of rights or remedies.

     8.19  SURVIVAL.  The  provisions  of Articles  III, IV, V, VI, VII and VIII
shall survive any termination of this Agreement.

     IN WITNESS  WHEREOF,  LightTouch  and  Medical  Director  have  caused this
Agreement to be executed by their duly authorized  respective officers as of the
Effective Date.

                                   LIGHTTOUCH VEIN & LASER, INC.

                                   By: /s/ Gregory F. Martini
                                       --------------------------
                                   Title: /s/ President
                                         ------------------------

                                   /s/ Harley F. Freiberger
                                   ------------------------------
                                   HARLEY F. FREIBERGER, M.D.

Charleston:  182738 v.6                  11
<PAGE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]